cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. as a leader in muscle biology and the mechanics of muscle performance, we're developing small molecule drug candidates specifically engineered to increase muscle function and contractility.
Company profile
Ticker
CYTK
Exchange
Website
CEO
Robert Blum
Employees
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
943291317
CYTK stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
8 Apr 24
DEF 14A
Definitive proxy
8 Apr 24
8-K
Other Events
5 Apr 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
Cytokinetics Reports Fourth Quarter 2023 Financial Results
27 Feb 24
8-K
Departure of Directors or Certain Officers
2 Feb 24
8-K
Other Events
27 Dec 23
8-K
Material Modifications to Rights of Security Holders
17 Nov 23
10-Q
2023 Q3
Quarterly report
3 Nov 23
8-K
Cytokinetics Reports Third Quarter 2023 Financial Results
2 Nov 23
Transcripts
CYTK
Earnings call transcript
2023 Q4
27 Feb 24
CYTK
Earnings call transcript
2023 Q3
2 Nov 23
CYTK
Earnings call transcript
2023 Q2
3 Aug 23
CYTK
Earnings call transcript
2023 Q1
4 May 23
CYTK
Earnings call transcript
2022 Q4
1 Mar 23
CYTK
Earnings call transcript
2022 Q3
3 Nov 22
CYTK
Earnings call transcript
2022 Q2
7 Aug 22
CYTK
Earnings call transcript
2022 Q1
5 May 22
CYTK
Earnings call transcript
2021 Q4
25 Feb 22
CYTK
Earnings call transcript
2021 Q3
4 Nov 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 100.07 mm | 100.07 mm | 100.07 mm | 100.07 mm | 100.07 mm | 100.07 mm |
Cash burn (monthly) | (no burn) | 514.25 k | 40.76 mm | 41.32 mm | 32.07 mm | 36.54 mm |
Cash used (since last report) | n/a | 3.43 mm | 271.99 mm | 275.75 mm | 214.02 mm | 243.86 mm |
Cash remaining | n/a | 96.63 mm | -171.92 mm | -175.68 mm | -113.95 mm | -143.80 mm |
Runway (months of cash) | n/a | 187.9 | -4.2 | -4.3 | -3.6 | -3.9 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 256 |
Opened positions | 28 |
Closed positions | 25 |
Increased positions | 93 |
Reduced positions | 77 |
13F shares | Current |
---|---|
Total value | 3.19 tn |
Total shares | 116.76 mm |
Total puts | 1.33 mm |
Total calls | 490.04 k |
Total put/call ratio | 2.7 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 15.63 mm | $460.60 bn |
FMR | 11.99 mm | $353.25 bn |
Vanguard | 10.74 mm | $316.50 bn |
Wellington Management | 7.99 mm | $235.28 bn |
STT State Street | 5.27 mm | $155.39 bn |
Eastern Capital | 3.06 mm | $64.35 mm |
Biotechnology Value Fund L P | 2.73 mm | $54.56 mm |
Polar Capital | 2.65 mm | $78.20 bn |
RTW Investments | 2.57 mm | $75.84 bn |
Integrated Core Strategies | 2.57 mm | $27.28 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
12 Apr 24 | Fady Ibraham Malik | Common Stock | Gift | Dispose G | No | No | 0 | 150 | 0.00 | 138,417 |
9 Apr 24 | Fady Ibraham Malik | Common Stock | Sell | Dispose S | No | No | 74.32 | 4,000 | 297.28 k | 138,567 |
9 Apr 24 | Fady Ibraham Malik | Common Stock | Sell | Dispose S | No | No | 74.31 | 28,605 | 2.13 mm | 142,567 |
9 Apr 24 | Fady Ibraham Malik | Common Stock | Option exercise | Acquire M | No | No | 6.67 | 28,605 | 190.80 k | 171,172 |
9 Apr 24 | Fady Ibraham Malik | NQSO Common Stock | Option exercise | Dispose M | No | No | 6.67 | 28,605 | 190.80 k | 0 |
14 Mar 24 | Robert I Blum | Common Stock | Grant | Acquire A | No | No | 0 | 61,490 | 0.00 | 461,221 |
14 Mar 24 | Robert I Blum | NQSO Common Stock | Grant | Acquire A | No | No | 63.75 | 69,464 | 4.43 mm | 69,464 |
14 Mar 24 | Robert I Blum | Incentive Stock Option Common Stock | Grant | Acquire A | No | No | 63.75 | 1,568 | 99.96 k | 1,568 |
14 Mar 24 | Fady Ibraham Malik | Common Stock | Grant | Acquire A | No | No | 0 | 21,333 | 0.00 | 142,567 |
14 Mar 24 | Fady Ibraham Malik | NQSO Common Stock | Grant | Acquire A | No | No | 63.75 | 23,103 | 1.47 mm | 23,103 |
News
Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress
10 Apr 24
Needham Reiterates Buy on Cytokinetics, Maintains $108 Price Target
9 Apr 24
Truist Securities Reiterates Buy on Cytokinetics, Maintains $86 Price Target
8 Apr 24
Cytokinetics Says It Presented Additional 48-Week Data From FOREST-HCM, The Open Label Extension Clinical Study of Aficamten, At The American College Of Cardiology 73ʳᵈ Annual Scientific Session
5 Apr 24
$100 Invested In Cytokinetics 5 Years Ago Would Be Worth This Much Today
3 Apr 24
Press releases
Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress
10 Apr 24
Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73ʳᵈ Annual Scientific Session
5 Apr 24
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2 Apr 24
Cytokinetics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
1 Apr 24
Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 73rd Annual Scientific Session
25 Mar 24